These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16941618)

  • 1. Off-resonance saturation as a means of generating contrast with superparamagnetic nanoparticles.
    Zurkiya O; Hu X
    Magn Reson Med; 2006 Oct; 56(4):726-32. PubMed ID: 16941618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility-based MRI contrast of the CSF by intravascular superparamagnetic nanoparticles.
    Yu O; Namer IJ; Steibel J; Eclancher B; Poulet P; Chambron J
    MAGMA; 1995; 3(3-4):169-72. PubMed ID: 8749736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theoretical and experimental study of ON-Resonance Saturation, an MRI sequence for positive contrast with superparamagnetic nanoparticles.
    Delangre S; Vuong QL; Henrard D; Magat J; Po C; Gallez B; Gossuin Y
    J Magn Reson; 2015 Mar; 252():151-62. PubMed ID: 25700117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental investigation of the delivery pathway of ultrasmall superparamagnetic iron oxide to lymph nodes.
    Frija G; Clément O; Le Guen O; Cuénod CA; Siauve N; Benderbous S
    Acad Radiol; 1996 Aug; 3 Suppl 2():S299-300. PubMed ID: 8796586
    [No Abstract]   [Full Text] [Related]  

  • 5. Limits of detection of SPIO at 3.0 T using T2 relaxometry.
    Dahnke H; Schaeffter T
    Magn Reson Med; 2005 May; 53(5):1202-6. PubMed ID: 15844156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin and uptake of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) in human monocyte-macrophages: implications for magnetic resonance imaging.
    Müller K; Skepper JN; Tang TY; Graves MJ; Patterson AJ; Corot C; Lancelot E; Thompson PW; Brown AP; Gillard JH
    Biomaterials; 2008 Jun; 29(17):2656-62. PubMed ID: 18377983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of ultrasmall superparamagnetic iron oxide particles for liver imaging.
    Saini S; Edelman RR; Li W; Petersein J; Hahn PF
    Acad Radiol; 1996 Aug; 3 Suppl 2():S409-12. PubMed ID: 8796616
    [No Abstract]   [Full Text] [Related]  

  • 8. MR lymphography: evidence of extravasation of superparamagnetic nanoparticles into the lymph.
    Clement O; Rety F; Cuenod CA; Siauve N; Carnot F; Bordat C; Siche M; Frija G
    Acad Radiol; 1998 Apr; 5 Suppl 1():S170-2; discussion S183-4. PubMed ID: 9561073
    [No Abstract]   [Full Text] [Related]  

  • 9. MRI detection of macrophages labeled using micrometer-sized iron oxide particles.
    Williams JB; Ye Q; Hitchens TK; Kaufman CL; Ho C
    J Magn Reson Imaging; 2007 Jun; 25(6):1210-8. PubMed ID: 17520727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [MR contrast agent: resovist (SH U 555A)].
    Nakajima H; Ichikawa T
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():328-32. PubMed ID: 11761967
    [No Abstract]   [Full Text] [Related]  

  • 11. Magnetic resonance imaging of liver metastases: experimental comparison of anionic and conventional superparamagnetic iron oxide particles with a hepatobiliary contrast medium during dynamic and uptake phases.
    Kaufels N; Korn R; Wagner S; Schink T; Hamm B; Taupitz M; Schnorr J
    Invest Radiol; 2008 Jul; 43(7):496-503. PubMed ID: 18580332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging.
    Briley-Saebo K; Bjørnerud A; Grant D; Ahlstrom H; Berg T; Kindberg GM
    Cell Tissue Res; 2004 Jun; 316(3):315-23. PubMed ID: 15103550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and quality test of superparamagnetic iron oxide labeled antisense oligodeoxynucleotide probe: a preliminary study.
    Wen M; Li B; Ouyang Y; Luo Y; Li S
    Ann Biomed Eng; 2009 Jun; 37(6):1240-50. PubMed ID: 19337837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focal nodular hyperplasia of the liver: usefulness of superparamagnetic iron oxide-enhanced magnetic resonance imaging.
    Okada T; Sasaki F; Kamiyama T; Nakagawa T; Nakanishi K; Kobayashi R; Itoh T; Ota S; Todo S
    J Pediatr Surg; 2005 Mar; 40(3):E21-5. PubMed ID: 15793708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histochemical detection of ultrasmall superparamagnetic iron oxide (USPIO) contrast medium uptake in experimental brain ischemia.
    Schroeter M; Saleh A; Wiedermann D; Hoehn M; Jander S
    Magn Reson Med; 2004 Aug; 52(2):403-6. PubMed ID: 15282824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10.
    Islam T; Wolf G
    Cancer Biomark; 2009; 5(2):69-73. PubMed ID: 19414923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of superparamagnetic iron-oxide MR contrast agents in the rat.
    Majumdar S; Zoghbi SS; Gore JC
    Invest Radiol; 1990 Jul; 25(7):771-7. PubMed ID: 2391194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of contrast enhancement with iron oxides.
    Frija G; Clément O; de Kerviler E
    Invest Radiol; 1994 Jun; 29 Suppl 2():S75-7. PubMed ID: 7928276
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI.
    Chen TJ; Cheng TH; Chen CY; Hsu SC; Cheng TL; Liu GC; Wang YM
    J Biol Inorg Chem; 2009 Feb; 14(2):253-60. PubMed ID: 18975017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive contrast MR-lymphography using inversion recovery with ON-resonant water suppression (IRON).
    Korosoglou G; Tang L; Kedziorek D; Cosby K; Gilson WD; Vonken EJ; Schär M; Sosnovik D; Kraitchman DL; Weiss RG; Weissleder R; Stuber M
    J Magn Reson Imaging; 2008 May; 27(5):1175-80. PubMed ID: 18425827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.